Insect Cell N-Glycosylation Humanization via Gene Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant protein production systems, such as insect cells, often produce proteins with immunogenic glycosylation patterns that can trigger immune reactions in humans, limiting their therapeutic efficacy and safety.
Innovation Solution
Genetically modified Drosophila cells with disrupted fdl and FucT6 genes, combined with the insertion of functional GlcNAcT I and GlcNAcT II genes, are used to produce proteins with a human-like N-glycosylation pattern, reducing immunogenicity and enhancing protein stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If insect cells are used for recombinant protein production, then production speed and ability to produce difficult proteins are improved, but the proteins acquire non-human glycosylation patterns that trigger immune reactions
Solution Approach 1:
The patent applies parameter changes by modifying the glycosylation parameters of insect cells through genetic engineering. Specifically, the fdl gene is disrupted to prevent formation of pauci-mannosidic glycans, and human GlcNAcT I and GlcNAcT II genes are inserted to enable formation of complex N-glycans with terminal GlcNAc residues. This transforms the glycosylation pattern from immunogenic insect-type to non-immunogenic human-like type, resolving the contradiction between production efficiency and immune compatibility
Solution Approach 2:
The patent uses human glycosyltransferase genes (GlcNAcT I and GlcNAcT II) as intermediary elements to bridge the gap between insect cell machinery and human glycosylation requirements. These inserted genes act as mediators that redirect the insect cell's N-glycosylation pathway to produce human-like complex glycans, thereby enabling insect cells to produce therapeutically acceptable glycosylated proteins while maintaining their high productivity advantages
2Object-affected harmful factors
If mammalian expression systems are used to achieve human-like glycosylation, then immunogenicity is reduced, but production cost and complexity increase
Solution Approach 1:
The patent applies the copying principle by transferring specific human glycosylation genes (GlcNAcT I and GlcNAcT II) into insect cells. Instead of using entire complex mammalian expression systems, the invention copies only the essential genetic elements required to produce human-like N-glycans. This simplified copying approach enables insect cells to acquire human glycosylation capabilities without the full complexity and cost associated with mammalian cell culture systems
Solution Approach 2:
The patent demonstrates universality by showing that insect cells, when genetically modified with human glycosyltransferase genes, can perform both insect cell advantages (high productivity, ease of culture) and human glycosylation functions (production of non-immunogenic complex N-glycans). This multi-functional insect cell system combines the benefits of different expression systems, making them universally applicable for producing both difficult-to-express proteins and therapeutically acceptable glycosylated products
Data Source
AI summary
The present disclosure provides genetically modified insect cells that can produce glycosylated expression products having a human-like glycosylation pattern. In particular, the cells comprise disruption of the fdl and/or FucT6 genes. Also provided is expression systems and methods for recombinant protein production.